METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can radiation kickstart the immune system against stubborn cancers?
Disease control Recruiting nowThis study is for people with advanced gastrointestinal cancers that are getting worse despite immunotherapy. It tests whether giving focused radiation to one tumor can help the immune system attack other tumors throughout the body. About 28 participants will receive radiation wh…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 26, 2026 06:10 UTC
-
New combo attack on stomach cancer shows early promise
Disease control Recruiting nowThis early-phase trial tests two drugs, pembrolizumab and lenvatinib, in about 15 people with advanced stomach or gastroesophageal cancer that has spread or can't be surgically removed. Pembrolizumab helps the immune system fight cancer, while lenvatinib blocks enzymes that help …
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 06:07 UTC
-
New drug duo targets hard-to-treat stomach cancers
Disease control Recruiting nowThis early-stage study tests two drugs together for people with HER2-positive stomach cancer or other solid tumors that have spread or can't be removed. The drugs, trastuzumab deruxtecan and azenosertib, aim to kill cancer cells more effectively. The main goals are to find the be…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:06 UTC
-
Could a stronger chemo cocktail extend life for stomach cancer patients?
Disease control Recruiting nowThis study compares two chemotherapy combinations for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery or has spread. About 382 participants will receive either the standard FOLFOX chemo (with or without the immunothe…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 26, 2026 05:50 UTC
-
Could a common heart drug boost cancer treatment?
Disease control Recruiting nowThis study tests whether adding propranolol (a beta-blocker used for heart conditions) to standard chemotherapy and immunotherapy (pembrolizumab) can improve treatment for advanced esophageal or gastroesophageal junction cancer that cannot be surgically removed. About 40 adults w…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 26, 2026 05:49 UTC
-
New drug combo shows promise in advanced stomach cancer trial
Disease control Recruiting nowThis study is for people with advanced stomach or esophageal cancer that has spread. It tests whether adding the immunotherapy drug nivolumab to the usual two-drug treatment (paclitaxel and ramucirumab) helps control the cancer longer. About 224 participants will be randomly assi…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:48 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps the immune syst…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug combo hopes to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a combination of two drugs—trifluridine/tipiracil (a chemotherapy) and talazoparib (a targeted therapy)—in people with advanced colorectal or gastroesophageal cancers that have spread. The main goals are to find the safest dose and understand side eff…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New immune cocktail targets tough stomach cancers
Disease control Recruiting nowThis study tests a mix of immune cells (agenT-797) and three immunotherapy drugs (botensilimab, balstilimab, ramucirumab) plus chemotherapy (paclitaxel) for people with advanced stomach, esophageal, or gastro-esophageal junction cancer that has worsened after one prior treatment.…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC